Jane Street Group LLC Grows Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Jane Street Group LLC lifted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1,064.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 345,092 shares of the company's stock after buying an additional 315,456 shares during the period. Jane Street Group LLC owned approximately 0.48% of Kiniksa Pharmaceuticals worth $8,624,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quarry LP acquired a new position in Kiniksa Pharmaceuticals during the third quarter worth $50,000. CWM LLC boosted its holdings in Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $61,000 after acquiring an additional 1,998 shares during the period. nVerses Capital LLC acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at about $80,000. Ashton Thomas Private Wealth LLC purchased a new stake in Kiniksa Pharmaceuticals during the second quarter worth about $100,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $189,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA traded up $0.06 during trading on Friday, reaching $20.20. The company's stock had a trading volume of 192,503 shares, compared to its average volume of 397,825. The business's fifty day moving average price is $23.25 and its 200-day moving average price is $23.05. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -144.29 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. During the same quarter last year, the firm earned ($0.20) earnings per share. The company's revenue was up 67.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Evercore ISI increased their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a "buy" rating and a $40.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $36.60.

Insider Activity

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 17,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares of the company's stock, valued at approximately $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 44,592 shares of company stock worth $1,110,364. Company insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.